Cell and gene therapy manufacturing: the next generation of startups

4BIO Capital portfolio company Ascend Gene and Cell Therapies has featured in a BioPharma Dive article from the State of Play series that takes a look at the emerging cell and gene therapy manufacturing companies

Developing a new drug is a long, expensive process that comes with a high risk of failure, often because would-be medicines are unsafe or ineffective. For companies specializing in cell or gene therapies, an equally pressing concern is figuring out how to reliably make their products. Unlike small molecule or antibody drugs, genetic medicines typically involve a variety of specialized parts woven together through a complex process.

Read the full article at www.biopharmadive.com.